Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M07D1 in HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors
NCT06031584Phase 2Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BL-M07D1 in urinary tract tumor and gastrointestinal tumor, sponsored by Biokin Pharmaceutical. Primary endpoints: Recommended Phase II Dose at 24 months and Objective Response Rate at 24 months. Started Jan 2024; status: recruiting.
02
Drugs
BL-M07D1
03
Conditions
urinary tract tumorgastrointestinal tumor
Beyond the preview
Go deeper on NCT06031584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06031584.